Google
Trusted Resources: News & Events
Latest announcements and gatherings
Phase 1 trial to test under-the-skin injection of sevuparin in sickle cell patients
Modus Therapeutics is going to launch a Phase 1 clinical study in the United States to evaluate the potential of its lead candidate sevuparin for the treatment of sickle cell disease (SCD).
In the trial, the company will broaden the clinical scope and usefulness of sevuparin to treat sickle cell disease by testing its safety when administrated subcutaneously (under the skin).
This follows the acceptance by the U.S Food and Drug Administration (FDA) of an investigational new drug (IND) application for sevuparin.
Modus Therapeutics is currently evaluating the therapeutic activity of sevuparin to manage painful crisis, also known as acute vaso-occlusive crisis (VOC), in patients with sickle cell disease in an ongoing Phase 2 study (NCT02515838).
+myBinderRelated Content
-
Novo Nordisk obtains licence for sickle cell disease programNovo Nordisk inked a global licence deal...
-
Red blood cell transfusion to treat or prevent complications in sickle cell disease: An overview of Cochrane reviewsBackground: Globally, sickle cell disea...
-
Pediatric pain screening identifies youth at risk of chronic pain in sickle cell diseaseBackground: This study aimed to evaluat...
-
Living With Unpredictable Pain: A Sickle Cell Disease StoryGrowing up, Vismel Marquez wanted to joi...
-
Review Board Finds Global Blood’s Sickle Cell Disease Therapy Voxelotor Is SafeAn independent review board has found Gl...
-
Living With Sickle Cell Disease Is a Constant Battle With Pain, According to one Woman Who Has It“You don’t look sick.” That’s ...
-
Phase 3 Trial Recruiting to Test Rivipansel for Vaso-Occlusive Crisis in SCDGlycoMimetics, in collaboration with Pfi...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.